It is currently Thu Oct 23, 2014 10:14 am

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Th1 and Th2 responses: what are they?

This paper makes a few oft heard terms a little more understandable. I'm not certain of the exact date but I THINK it's from August 12, 2000.
Bob

Th1 and Th2 responses: what are they?

Abi Berger, science editor.

BMJ

Cytokines are the hormonal messengers responsible for most of the biological effects in the immune system, such as cell mediated immunity and allergic type responses. Although they are numerous, cytokines can be functionally divided into ...
Read more : Th1 and Th2 responses: what are they? | Views : 3164 | Replies : 15 | Forum : General Discussion


SF1019

Hello all.
I just joined today. I read back and found some things on SF1019. I found a lot of negative. As I read I understood that for the most part people who were commenting were frustrated because of lack of info. I have found that lack of knowledge regarding drug development and how the process works can be confusing and also make persons who are desperate for a cure find fault and look for ...
Read more : SF1019 | Views : 29267 | Replies : 42 | Forum : Aimspro


Campath Phase II results

Here are the Phase II Campath results.

http://www.genzyme.com/corp/investors/G ... 050207.asp

I think they are impressive for those with RR MS (I'm biased because I've seen excellent results following my first infusion last November). And the impressive reduction in relapses is when compared with Rebif.

These sorts of treatments are riskier than the CRAB drugs, but the risks identified to date can be monitored and treated. And you don't see ...
Read more : Campath Phase II results | Views : 3742 | Replies : 17 | Forum : Drug Pipeline


Betaferon and delayed disability

Tuesday - May 1, 2007

First-of-its-Kind Data Show:
Immediate Treatment of Early MS Patients with Betaferon® Significantly Delayed Permanent Disability
Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment


Berlin – Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as ...
Read more : Betaferon and delayed disability | Views : 1048 | Replies : 0 | Forum : Drug Pipeline


Alemtuzumab

Hi all,

It is possible to access the abstracts from the AAN meeting...Below is an example of one that I located (I'm not sure if it has been mentioned yet...if it has, I apologize ahead of time)...there are more articles on prospective meds as well as a host of other important info...

the link is

http://www.abstracts2view.com/aan2007bo ... 2007-05-01

best,

TOL

Efficacy of Alemtuzumab in Treatment-Naive Relapsing-Remitting Multiple Sclerosis: ...
Read more : Alemtuzumab | Views : 1242 | Replies : 1 | Forum : Drug Pipeline


Laquinimod trial results

Don't appear that impressive - but it's oral.

http://c.moreover.com/click/here.pl?j913561424&w=464753
Read more : Laquinimod trial results | Views : 1482 | Replies : 3 | Forum : Drug Pipeline


Rituxan® Phase II Data in Patients with RRMS

Rituxan® Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

Rituxan® Significantly Reduced Signs Of Disease Activity As Measured By MRI and Relapse


BOSTON--(BUSINESS WIRE)--Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan® (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is ...
Read more : Rituxan® Phase II Data in Patients with RRMS | Views : 1144 | Replies : 2 | Forum : Drug Pipeline




Professor Scolding

Dear all,

Professor Neil Scolding is one of the UK's leading lights in stem cell research for MS (using an individual's own stem cells). There was some talk about him starting some early trials this year and he is being funded by the UK MS Society in this area. Here is an article about his work:

Stem cell treatment may ease MS suffering

Irish Times - May. 01, 2007


The suffering of multiple sclerosis ...
Read more : Professor Scolding | Views : 1884 | Replies : 1 | Forum : Stem Cells


CERE-120 in Parkinson's

I know it doesn't mention MS but I think it's very encouraging that gene therapy is helping a neurdegenerative disease like Parkinson's. It could help us one day too.



Gene Therapy
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

April 30th, 2007

(NewsRx.com) -- Ceregene, Inc., a biopharmaceutical company, today presented long term follow-up data from a Phase 1 clinical trial of CERE-120, a ...
Read more : CERE-120 in Parkinson's | Views : 1044 | Replies : 0 | Forum : Drug Pipeline


 

Login  •  Register


Statistics

Total posts 220816 • Total topics 22883 • Total members 14451


Contact us | Terms of Service